Guardion Health Sciences Inc

Guardion Health Sciences, Inc.is a clinical nutrition and diagnostics company, which develops medical foods and medical devices in the ocular health space and develops nutraceutical products to provide supportive health benefits to consumers. The company was founded by Michael Favish in 2009 and is headquartered in Houston, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardion Health Sciences, Inc. engages in the development and distribution of clinically supported dietary supplements and medical foods. The firm also offers science-based products and devices designed to support healthcare professionals, providers, patients, and consumers. The company was founded by Michael Favish in December 2009 and is headquartered in Houston, TX.

Guardion Health Sciences, Inc.'s (GHSI) CEO Dr.

Newly-Appointed CFO Andrew Schmidt Brings  Extensive and Wide-Ranging Public Company Experience

Guardion Health Sciences Adds Experienced Vice President and Chief Financial Officer to Executive Management Team

The Only Computer Vision Testing Device to Combine Standardized Contrast Sensitivity Testing with a Full Suite of Clinical Vision Tests

Guardion Subsidiary VectorVision Receives Approval from Korean Intellectual Property Office for CSV-2000 Trademark

Patent Application Will Add to   Guardion’s Intellectual Property Portfolio

Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to Eye Disease

Fulfills Initial Order of Astramern from Astramune Sdn Bhd, a Subsidiary of Ho Wah Genting Berhad

Guardion Health Sciences Completes Delivery of $875,000 Order to Malaysian Corporate Customer

San Diego, California, June  15, 2020  (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced today that its Board of Directors has appointed Dr. David Evans, Ph.D. as the Company's Interim President and Interim Chief Executive Officer effective immediately. Dr. Evans has served as the Company’s Chief Science Officer and was the founder of the Company’s subsidiary, VectorVision. Dr. Evans joined the Guardion Board of Directors effective with the Company’s acquisition of VectorVision on September 29, 2017.

Guardion Health Sciences Names Dr. David Evans as Interim President and Interim Chief Executive Officer

Avinger

KAR Auction Services

There are pockets of the stock market that look far too overvalued to ignore, and our deep learning algorithms paired with our Artificial Intelligence (“AI”) technology has identified the top short targets for today.

Top Companies To Short In A Potentially Overbought Market

Bandwidth

Capital One

EyePoint Pharmaceuticals

Heat Biologics

The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been this year.

Top Stocks To Short As Stock Market Surges

-- First study to provide a head-to-head comparison of two commercially available supplements with regard to the changes in serum levels of carotenoids, visual function and macular pigment optical density (MPOD)

Lumega-Z® Demonstrates Superiority in a Head-to-Head Study Showing Better Bioavailability of Carotenoids and Restoring Macular Pigment Density

– Presentation with live audio webcast on Wednesday, April 22 at 1:30 PM ET, immediately followed by an interactive Q&A session –

Guardion Health Sciences to Present at the April 2020 Virtual Investor Summit

- acuMMUNE now available for sale in the United States through online platforms -

Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant Complex

--Growing portfolio of synergistic assets and proprietary technologies

Guardion Health Sciences Reports 2019 Year End Results and Provides Corporate Update and Overview

- No immediate effect on the Company’s Nasdaq listing or the trading of its common stock -

Guardion Health Sciences Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

San Diego, California, March  06, 2020  (GLOBE NEWSWIRE) --  Guardion Health Sciences, Inc.  (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences company that develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols, today announced that it has received total gross proceeds of $3,510,630.00 during the period from February 28, 2020 through March 3, 2020 from the exercise of 10,265,000 warrants issued in the Company’s October 2019 follow-on offering at an exercise price of $0.342 per share.

Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants

Shares of actively-traded penny stock Guardion Health Sciences Inc (NASDAQ: GHSI) are advancing after the company announced an agreement for developing an immuno-supportive formula.

Penny Stock Ticks Higher On Deal To Develop Immune-Supportive Formula

Guardion® has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system.  The formula will be a unique and exclusive brand of HWGB

Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula

  Formulation will be First Nutraceutical Compound to be Introduced Under Guardion’s Recently Acquired NutriGuard Business Line

Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract Infections

San Diego, California, Jan.  07, 2020  (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a leader in the field of ocular health technologies and products, announced that it has hired John P. Troup, PhD to serve as President of the Company’s NutriGuard business line, which was acquired by the Company effective as of September 20, 2019. The NutriGuard business, with a 30-year operating history, is expected to provide the Company with a direct-to-consumer (“DTC”) capability. The Company’s objective is to develop NutriGuard into a globally-recognized and respected, physician-preferred nutraceuticals brand.

Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line

San Diego, CA, Oct.  30, 2019  (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), today announced the closing of its previously announced underwritten public offering of 24,500,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Series B warrants to purchase up to 24,500,000 shares of the Company’s common stock. Each share of common stock or pre-funded warrant was sold together with one Series B warrant to purchase one share of common stock at a combined price to the public of $0.342 per share and warrant. The shares of common stock or pre-funded warrants and the accompanying Series B warrants were sold together in this offering, but were issued separately and were immediately separable upon issuance. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses were approximately $8.4 million.

Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering

San Diego, CA, Oct.  28, 2019  (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced the pricing of an underwritten public offering of 24,500,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Series B warrants to purchase up to 24,500,000 shares of the Company’s common stock. Each share of common stock (or pre-funded warrants to purchase common stock in lieu thereof) is being sold together with one Series B warrant to purchase one share of common stock at a combined price to the public of $0.342 per share and Series B warrant. The shares of common stock or pre-funded warrants and the accompanying Series B warrants are being sold together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $8.4 million.

Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering

San Diego, California, Oct.  23, 2019  (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced that it has received approval from the USPTO for additional claims reflected in a new patent for its proprietary medical device, the MapcatSF®. The new patent will issue October 29, 2019 as U.S. Patent No. 10,456,028 and is a continuation patent on the original MapcatSF® patent, U.S. Patent No. 9,486,136. This second patent on the MapcatSF® covers new embodiments around the device that contain improvements related to the accuracy of intensity measurements made with the device, as well as patentably distinct features around photodiode detector calibrations. Also, there will be a patent term adjustment for the patent of 307 days.

Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF

 Study Results Show 40 Times Higher Blood Concentration Levels of Mesozeaxanthin From Lumega-Z, Guardion’s Flagship Medical Food, as compared to Standard AREDS2 Over-The-Counter Gel Caps

Guardion® Announces Statistically Significant Blood Assay Study Results

San Diego, California, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI), through its newly-formed wholly-owned subsidiary, NutriGuard Formulations, Inc., has acquired certain assets of NutriGuard Research, Inc. (“NutriGuard”). This acquisition, which was effective as of September 20, 2019, provides a direct-to-consumer (“DTC”) capability for the Company. Guardion is a leader in the field of ocular health technologies and products.

Guardion Health Sciences Acquires the NutriGuard Brand of Products

New Generation of Vision Testing Technology to be Introduced at Vision Expo West

Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test

Guardion Health Sciences, Inc (NASDAQ: GHSI) shares are trading higher after the company announced it received a patent from the Patents Registry in Hong Kong for its proprietary medical device, the MapcatSF.

News for Guardion Health Sciences Inc Stock (GHSI)